Table I.
Association of HUWE1 expression with survival of patients with cancer.
| Cancer type | n | P-value | HR (95% CI) | Endpoint | Dataset | Probe ID | ln (HR) |
|---|---|---|---|---|---|---|---|
| Bladder cancer | 30 | 3.05×10−2 | 3.42 (1.12–10.42) | Overall survival | GSE5287 | 208598_s_at | 1.2296 |
| Brain cancer | 74 | 3.16×10−2 | 0.23 (0.06–0.88) | Overall survival | GSE4412-GPL96 | 208598_s_at | −1.4783 |
| Breast cancer | 158 | 2.07×10−2 | 3.69 (1.22–11.15) | Overall survival | GSE3143 | 34372_at | 1.3054 |
| Breast cancer | 204 | 2.68×10−2 | 0.47 (0.24–0.92) | Relapse free survival | GSE12276 | 207783_x_at | −0.7499 |
| Breast cancer | 77 | 2.47×10−2 | 0.01 (0.00–0.57) | Relapse free survival | GSE9195 | 207783_x_at | −4.4615 |
| Breast cancer | 77 | 2.07×10−2 | 0.01 (0.00–0.45) | Distant metastasis free survival | GSE9195 | 207783_x_at | −5.2755 |
| Breast cancer | 136 | 3.91×10−3 | 0.26 (0.10–0.65) | Distant metastasis free survival | GSE12093 | 208598_s_at | −1.3632 |
| Breast cancer | 200 | 1.84×10−2 | 1.54 (1.08–2.21) | Distant Metastasis Free survival | GSE11121 | 208599_at | 0.4321 |
| Breast cancer | 117 | 3.52×10−2 | 7.17 (1.15–44.82) | Distant metastasis free survival | E-TABM-158 | 208599_at | 1.9697 |
| Breast cancer | 236 | 1.38×10−2 | 1.57 (1.10–2.24) | Disease specific survival | GSE3494-GPL96 | 214673_s_at | 0.44818 |
| Breast cancer | 236 | 1.25×10−2 | 5.04 (1.42–17.91) | Disease specific survival | GSE3494-GPL96 | 208598_s_at | 1.6168 |
| Breast cancer | 249 | 4.97×10−3 | 4.08 (1.53–10.89) | Disease Free Survival | GSE4922-GPL96 | 208598_s_at | 1.4066 |
| Breast cancer | 198 | 7.58×10−3 | 0.58 (0.39–0.87) | Distant metastasis free survival | GSE7390 | 207783_x_at | −0.5376 |
| Breast cancer | 198 | 5.87×10−3 | 0.57 (0.39–0.85) | Overall survival | GSE7390 | 207783_x_at | −0.5539 |
| Breast cancer | 198 | 2.54×10−2 | 0.63 (0.43–0.95) | Relapse free survival | GSE7390 | 207783_x_at | −0.4546 |
| Colorectal cancer | 177 | 3.56×10−2 | 0.22 (0.05–0.90) | Overall survival | GSE17536 | 214673_s_at | −1.5180 |
| Colorectal cancer | 55 | 3.20×10−4 | 0.01 (0.00–0.11) | Overall survival | GSE17537 | 214673_s_at | −4.8093 |
| Colorectal cancer | 55 | 2.01×10−4 | 0.00 (0.00–0.06) | Disease free survival | GSE17537 | 214673_s_at | −6.1017 |
| Colorectal cancer | 55 | 2.31×10−2 | 0.02 (0.00–0.58) | Overall survival | GSE17537 | 208599_at | −3.9563 |
| Colorectal cancer | 49 | 7.78×10−3 | 0.01 (0.00–0.32) | Disease specific survival | GSE17537 | 214673_s_at | −4.2781 |
| Esophagus cancer | 34 | 4.49×10−2 | 14.93 (1.06–209.58) | Overall survival | GSE11595 | 66423 | 2.7033 |
| Lung cancer | 104 | 1.09×10−2 | 0.01 (0.00–0.32) | Overall survival | jacob-00182-MSK | 207783_x_at | −4.9303 |
| Lung cancer | 204 | 4.40×10−3 | 18.26 (2.47–134.83) | Overall survival | GSE31210 | 207783_x_at | 2.9050 |
| Lung cancer | 204 | 1.27×10−5 | 28.08 (6.28–25.48) | Relapse free survival | GSE31210 | 207783_x_at | 3.3349 |
| Lung cancer | 204 | 1.44×10−2 | 0.38 (0.17–0.82) | Overall survival | GSE31210 | 236294_at | −0.9750 |
| Lung cancer | 204 | 3.28×10−6 | 0.26 (0.14–0.45) | Relapse free survival | GSE31210 | 236294_at | −1.3652 |
| Lung cancer | 138 | 6.40×10−3 | 0.00 (0.00–0.22) | Relapse free survival | GSE8894 | 236294_at | −5.4148 |
| Lung cancer | 138 | 2.50×10−2 | 0.15 (0.03–0.79) | Relapse free survival | GSE8894 | 208599_at | −1.8913 |
| Ovarian cancer | 133 | 4.32×10−2 | 1.95 (1.02–3.72) | Overall survival | DUKE-OC | 208599_at | 0.6675 |
| Prostate cancer | 281 | 5.88×10−3 | 1.80 (1.19–2.75) | Overall survival | GSE16560 | DAP4_0152 | 0.5900 |
| Skin cancer | 38 | 2.33×10−3 | 11.36 (2.38–54.33) | Overall survival | GSE19234 | 208599_at | 2.4304 |
| Soft tissue cancer | 140 | 6.89×10−4 | 3.20 (1.64–6.27) | Distant Recurrence Free survival | GSE30929 | 208598_s_at | 1.1640 |
HUWE1, E3 ubiquitin-protein ligase; HR, hazard ratio; CI, confidence interval.